TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Intervention in Cystic Fibrosis Exacerbation
Brief Summary: Individuals with cystic fibrosis (CF) develop chronic lung infections and suffer intermittent acute exacerbations of their lung disease. Most exacerbations are not treated until they cause increased symptoms, and patients seek medical attention. This proposal details a study of home lung function and symptom monitoring. Subjects will be randomly assigned to one of two groups: 1) home monitoring, in which spirometry and symptoms are recorded; or 2) standard care. The home monitoring data will be transmitted electronically to the study center. If spirometry or symptoms have deteriorated substantially, treatment for a CF pulmonary exacerbation will be initiated. It is anticipated that use of home monitoring will lead to earlier, more reliable recognition and treatment of exacerbations, which will translate into better lung health.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home monitoring; Type: ACTIVE_COMPARATOR; Interventions: Device: Home lung function and symptom monitoring | Intervention Type: DEVICE; Name: Home lung function and symptom monitoring; Assigned to Arm(s): Home monitoring
C: Arm Label: Exercise Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention
D: Arm Label: Fitbit plus personalised text messaging & Goal Setting; Type: EXPERIMENTAL; Interventions: Other: Fitness tracker with goal setting and text message feedback | Arm Label: Fitbit Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fitness Tracker only | Intervention Type: OTHER; Name: Fitness tracker with goal setting and text message feedback; Assigned to Arm(s): Fitbit plus personalised text messaging & Goal Setting | Intervention Type: OTHER; Name: Fitness Tracker only; Assigned to Arm(s): Fitbit Only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Intervention in Cystic Fibrosis Exacerbation
Brief Summary: Individuals with cystic fibrosis (CF) develop chronic lung infections and suffer intermittent acute exacerbations of their lung disease. Most exacerbations are not treated until they cause increased symptoms, and patients seek medical attention. This proposal details a study of home lung function and symptom monitoring. Subjects will be randomly assigned to one of two groups: 1) home monitoring, in which spirometry and symptoms are recorded; or 2) standard care. The home monitoring data will be transmitted electronically to the study center. If spirometry or symptoms have deteriorated substantially, treatment for a CF pulmonary exacerbation will be initiated. It is anticipated that use of home monitoring will lead to earlier, more reliable recognition and treatment of exacerbations, which will translate into better lung health.


Options:
A: Arm Label: SMS and Internet; Type: EXPERIMENTAL; Interventions: Behavioral: MD2ME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MD2ME; Assigned to Arm(s): SMS and Internet
B: Arm Label: Home monitoring; Type: EXPERIMENTAL; Interventions: Procedure: Home Monitoring | Arm Label: Clinical Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical Care | Intervention Type: PROCEDURE; Name: Home Monitoring; Assigned to Arm(s): Home monitoring | Intervention Type: OTHER; Name: Clinical Care; Assigned to Arm(s): Clinical Care
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home monitoring; Type: ACTIVE_COMPARATOR; Interventions: Device: Home lung function and symptom monitoring | Intervention Type: DEVICE; Name: Home lung function and symptom monitoring; Assigned to Arm(s): Home monitoring
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Brief Summary: The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.


Options:
A: Arm Label: ziprasidone injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ziprasidone | Arm Label: haloperidol + midazolam, injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol + midazolam | Arm Label: haloperidol + promethazine, injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidol+promethazine | Arm Label: olanzapine, injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Intervention Type: DRUG; Name: haloperidol+promethazine; Assigned to Arm(s): haloperidol + promethazine, injection | Intervention Type: DRUG; Name: haloperidol + midazolam; Assigned to Arm(s): haloperidol + midazolam, injection | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, injection | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): ziprasidone injection
B: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
C: Arm Label: Cariprazine 3mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 6mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Aripiprazole 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 3mg, Cariprazine 6mg | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Brief Summary: The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.


Options:
A: Arm Label: Cariprazine 3mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 6mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Aripiprazole 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 3mg, Cariprazine 6mg | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
C: Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Brief Summary: The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.


Options:
A: Arm Label: Cariprazine (3-6 mg/day); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine (6-9 mg/day); Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine (3-6 mg/day), Cariprazine (6-9 mg/day) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 003
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole (OPC-34712); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole (OPC-34712) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty
Brief Summary: The purpose of this study is to determine whether Adductor-Canal-Blockade is effective at reducing morphine consumption and pain, and at the same time improving mobilisation after total knee arthroplasty.


Options:
A: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline
B: Arm Label: Adductor-Canal-Blockade with Ropivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adductor-Canal-Blockade with Ropivacaine | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade with Ropivacaine; Assigned to Arm(s): Adductor-Canal-Blockade with Ropivacaine | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline
C: Arm Label: Active FNB, placebo ACB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Arm Label: Active ACB, placebo FNB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB
D: Arm Label: Adductor Canal Block:; Type: EXPERIMENTAL; Interventions: Procedure: Adductor Canal Block, Bupivacaine | Arm Label: Femoral Nerve Block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral Nerve Block, Bupivacaine | Intervention Type: PROCEDURE; Name: Adductor Canal Block, Bupivacaine; Assigned to Arm(s): Adductor Canal Block: | Intervention Type: PROCEDURE; Name: Femoral Nerve Block, Bupivacaine; Assigned to Arm(s): Femoral Nerve Block

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia
Brief Summary: The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.


Options:
A: Arm Label: PCI-32765; Type: EXPERIMENTAL; Interventions: Drug: PCI-32765 | Intervention Type: DRUG; Name: PCI-32765; Assigned to Arm(s): PCI-32765
B: Arm Label: ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): ibrutinib
C: Arm Label: Arm A (CLL/SLL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Arm Label: Arm B (NHL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Intervention Type: DRUG; Name: ABT-199; Assigned to Arm(s): Arm A (CLL/SLL subjects), Arm B (NHL subjects)
D: Arm Label: Bendamustine, rituximab, lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab, Drug: Lenalidomide | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multifaceted Prompting Intervention for Urban Children With Asthma
Brief Summary: The overall goal of this project is to evaluate whether a multifaceted prompting intervention, administered in the urban primary care office setting, reduces morbidity among urban children with asthma. This study builds on our experience with a pilot study in two urban continuity clinics, in which we found that prompting clinicians about asthma severity and care guidelines at the time of an office visit resulted in improved preventive care delivery to inner-city children. This type of prompting program has the potential to substantially improve care for impoverished children with asthma, and we propose to establish: 1) whether these findings can be replicated in a similar study including a larger sample of urban children from different types of practices, and 2) whether the positive effects can be enhanced by more specific prompting directed towards both the provider and the caregiver and by providing practice-level supports and feedback. We hypothesize that children receiving a multifaceted prompting intervention (MPI) will experience less asthma-related morbidity (defined by symptom-free days at the 2-month follow-up) compared to children receiving usual care. Our secondary hypothesis is that children receiving the MPI will receive improved preventive asthma care (defined by guideline-based corrective actions taken at the index visit) compared to children receiving usual care.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Multifaceted Prompting Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted Prompting Intervention MPI | Intervention Type: BEHAVIORAL; Name: Multifaceted Prompting Intervention MPI; Assigned to Arm(s): Multifaceted Prompting Intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: FL3X: Flexible Lifestyle Empowering Change | Intervention Type: BEHAVIORAL; Name: FL3X: Flexible Lifestyle Empowering Change; Assigned to Arm(s): Intervention
D: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Brief Summary: This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.


Options:
A: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm
B: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
C: Arm Label: Facemask and hand hygiene; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask, Behavioral: 62% Ethyl Alcohol Hand Sanitizer | Arm Label: Facemask only; Type: EXPERIMENTAL; Interventions: Behavioral: Ear Loop Procedure Mask | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Ear Loop Procedure Mask; Assigned to Arm(s): Facemask and hand hygiene, Facemask only | Intervention Type: BEHAVIORAL; Name: 62% Ethyl Alcohol Hand Sanitizer; Assigned to Arm(s): Facemask and hand hygiene
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: health education | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: hand hygiene, Device: face masks | Intervention Type: BEHAVIORAL; Name: hand hygiene; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: health education; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: face masks; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Brief Summary: This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.


Options:
A: Arm Label: Group 1 Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group 2 Enhanced Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Supplemental training, education and hygiene | Arm Label: Group 3 Chlorhexidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gluconate, Other: Supplemental training, education and hygiene | Intervention Type: DRUG; Name: Chlorhexidine gluconate; Assigned to Arm(s): Group 3 Chlorhexidine | Intervention Type: OTHER; Name: Supplemental training, education and hygiene; Assigned to Arm(s): Group 2 Enhanced Standard, Group 3 Chlorhexidine
B: Arm Label: Normal recommendations, no mask; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Normal recommendations AND mask; Type: EXPERIMENTAL; Interventions: Other: Surgical facial mask | Intervention Type: OTHER; Name: Surgical facial mask; Assigned to Arm(s): Normal recommendations AND mask
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Soap | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soap; Assigned to Arm(s): 1
D: Arm Label: Vitamin D and gargling; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3), Behavioral: Gargling | Arm Label: Vitamin D and general health advice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D3) | Arm Label: Placebo and general health advice; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Placebo and gargling; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Gargling, Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): Vitamin D and gargling, Vitamin D and general health advice | Intervention Type: BEHAVIORAL; Name: Gargling; Assigned to Arm(s): Placebo and gargling, Vitamin D and gargling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo and gargling, Placebo and general health advice

Answer: A